Leap Therapeutics’ (LPTX) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Leap Therapeutics (NASDAQ:LPTX) in a research report report published on Thursday morning,Benzinga reports.

Several other analysts also recently commented on LPTX. Baird R W downgraded shares of Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 29th. Robert W. Baird lowered Leap Therapeutics from an “outperform” rating to a “neutral” rating and lowered their target price for the stock from $9.00 to $1.25 in a research note on Wednesday, January 29th.

Leap Therapeutics Price Performance

Shares of NASDAQ:LPTX opened at $0.32 on Thursday. The company’s 50-day moving average price is $0.69 and its two-hundred day moving average price is $2.16. The stock has a market capitalization of $12.13 million, a PE ratio of -0.16 and a beta of 0.35. Leap Therapeutics has a one year low of $0.31 and a one year high of $4.79.

Leap Therapeutics (NASDAQ:LPTX) last issued its earnings results on Wednesday, March 26th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.02. On average, analysts anticipate that Leap Therapeutics will post -1.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of LPTX. Prosperity Wealth Management Inc. acquired a new stake in shares of Leap Therapeutics in the 4th quarter valued at $63,000. HighTower Advisors LLC acquired a new position in Leap Therapeutics during the third quarter worth about $65,000. HB Wealth Management LLC lifted its holdings in shares of Leap Therapeutics by 103.2% in the fourth quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock worth $150,000 after acquiring an additional 26,150 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Leap Therapeutics in the 4th quarter valued at approximately $107,000. Finally, Key Client Fiduciary Advisors LLC grew its holdings in shares of Leap Therapeutics by 12.2% during the 4th quarter. Key Client Fiduciary Advisors LLC now owns 361,253 shares of the company’s stock valued at $1,039,000 after purchasing an additional 39,330 shares during the last quarter. Institutional investors and hedge funds own 30.46% of the company’s stock.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.